References
- Heidemann LN, Hartwell D, Heidemann CH, et al. The relation between endometriosis and ovarian cancer—a review. Acta Obstet Gynecol Scand. 2014;93:20–31.
- Nishida M, Watanabe K, Sato N, et al. Malignant transformation of ovarian endometriosis. Gynecol Obstet Invest. 2000;50:18–25.
- Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol. 2012;124:164–169.
- Kawaguchi R, Tsuji Y, Haruta S. Clinicopathologic features of ovarian cancer in patients with ovarian endometrioma. J Obstet Gynaecol Res. 2008;34:872–877.
- Saeng-Anan U, Pantasri T, Neeyalavira V, et al. Sonographic pattern recognition of endometriomas mimicking ovarian cancer. Asian Pac J Cancer Prev. 2013;14:5409–5413.
- Vercellini P, Buggio L, Frattaruolo MP, et al. Medical treatment of endometriosis-related pain. Best Pract Res Clin Obstet Gynaecol. 2018;51:68–91.
- Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534–1544.
- Johnson NP, Hummelshoj L, Adamson GD, et al. World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod. 2017;32:315–324.
- Zapardiel L, Gorostidi M, Ravaggi A, et al. Utility serum marker HE4 for the differential diagnosis between endometriosis and adnexal malignancy. Int J Gynecol Cancer. 2016;26:52–55.
- Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–1319.
- Montagnana M, Lippi G, Danese E, et al. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer. 2009;101:548.
- Anastasi E, Granato T, Falzarano R, et al. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. J Ovarian Res. 2013;6:44.
- Moore RG, McMeekin DS, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–46.
- Shin JJ, Lee YJ, Kim R, et al. Analysis of falsely elevated risk of ovarian malignancy algorithm in women with ovarian endometrioma. Obstet Gynecol Sci. 2016;59:295–302.
- Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol. 2018;131:557–571.
- Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–412.
- Kvaskoff M, Horne AW, Missmer SA. Informing women with endometriosis about ovarian cancer risk. Lancet. 2017;390:2433–2434.
- Somigliana E, Berlanda N, Benaglia L, et al. Surgical excision of endometriomas and ovarian reserve: a systematic review on serum antimüllerian hormone level modifications. Fertil Steril. 2012;98:1531–1538.